Kivizidiale

Timolol and Travoprost, the active ingredients in Kivizidiale, are a beta‑blocker and prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is indicated for conditions affecting intra‑ocular pressure within the glaucoma and ocular hypertension disease family. Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. Adjunctive therapy in patients requiring multiple mechanisms: provides combined beta‑blocker and prostaglandin effects for enhanced IOP control.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision shortly after instillation - Redness of the eye - Dry eye or foreign‑body sensation - Mild headache - Transient ocular discomfort

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Worsening of glaucoma or uncontrolled IOP - Significant bradycardia or hypotension - Bronchospasm in susceptible individuals - Persistent eye pain or vision loss - Corneal ulceration or infection

Kivizidiale requires careful patient assessment and monitoring. Assess cardiovascular status: timolol may affect heart rate and blood pressure. Screen for respiratory disease: avoid in patients with asthma or COPD. Monitor intra‑ocular pressure: ensure adequate pressure reduction after initiation. Avoid use in patients with severe ocular inflammation or infection. Store at room temperature: keep in original container, protect from light and moisture.

Kivizidiale may interact with other systemic or ocular agents. Major Interactions (Avoid): - Concurrent non‑selective beta‑blockers: risk of additive systemic beta‑blockade. - Other ocular beta‑blocker drops: may cause excessive IOP lowering. Moderate Interactions (Monitor Closely): - Systemic carbonic anhydrase inhibitors: potential additive IOP‑lowering effect. - Anticholinergic eye drops: may influence ocular surface tolerance. - Topical NSAIDs: increased risk of corneal irritation. - Systemic steroids: possible alteration of IOP response.